Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GHSR | Q92847 | 5/20 | 0.47 |
| ▸ | YAP1 | P46937 | 3/20 | 0.44 |
| ▸ | GRIN1 | Q05586 | 3/20 | 0.42 |
| ▸ | GRIN2B | Q13224 | 3/20 | 0.42 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.42 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.42 |
| ▸ | RORC | P51449 | 1/20 | 0.41 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | CA4 | P22748 | 1/20 | 0.41 |
| ▸ | CA5A | P35218 | 1/20 | 0.41 |
| ▸ | CA7 | P43166 | 1/20 | 0.41 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.41 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.41 |
| ▸ | TACR1 | P25103 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3027212 | 1.00 | GHSR (0.47) | GHSRYAP1GRIN1GRIN2BPRMT5 | |
| SCHEMBL3020609 | 0.82 | ESR2 (0.48) | RORCPDE4BTACR1 | |
| SCHEMBL3020607 | 0.82 | ESR2 (0.48) | RORCPDE4BTACR1 | |
| SCHEMBL3024958 | 0.82 | RORC (0.43) | GPR119RORCPDE4BTACR1 | |
| SCHEMBL3024960 | 0.82 | RORC (0.43) | GPR119RORCPDE4BTACR1 | |
| SCHEMBL31136414 | 0.79 | GHSR (0.53) | GHSRYAP1PRMT5 | |
| SCHEMBL2478613 | 0.77 | GHSR (0.49) | GHSRYAP1PRMT5GPR119 | |
| SCHEMBL3018337 | 0.77 | GRIN1 (0.48) | GRIN1GRIN2BCA12 | |
| SCHEMBL3018340 | 0.77 | GRIN1 (0.48) | GRIN1GRIN2BCA12 | |
| SCHEMBL3018338 | 0.77 | GRIN1 (0.48) | GRIN1GRIN2BCA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100210680-A1 | TRICYCLIC HETEROCYCLIC DERIVATIVES | N.V. ORGANON | 2010-08-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100210680-A1 | TRICYCLIC HETEROCYCLIC DERIVATIVES | TPH1, HTR2C, TPH2 | GHSR 599/4885YAP1 2779/4885GRIN1 272/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.